Leukemias expressing the constitutively activated tyrosine kinases (TKs) BCR-ABL1 and FLT3/ITD activate signaling pathways that increase genomic instability through generation of reactive oxygen species (ROS), DNA double-strand breaks (DSBs) and error-prone repair. The non-homologous endjoining (NHEJ) pathway is a major pathway for DSB repair and is highly aberrant in TK-activatedleukemias; an alternative form of NHEJ (ALT-NHEJ) predominates, evidenced by increased expression of DNA ligase IIIα (LIG3) and poly (ADP-ribose) polymerase (PARP1), increased frequency of large genomic deletions, and repair using DNA sequence microhomologies. This study, 
Introduction
Constitutively activated tyrosine kinases (TKs) BCR-ABL1 and FLT3/ITD generate increased levels of reactive oxygen species (ROS), DNA damage including double-strand breaks (DSBs), and abnormal repair that is highly error-prone. Together, these features result in acquisition of genomic alterations which have the potential to drive disease progression and resistance to therapy (1, 2) . DSBs are repaired by two pathways, homologous recombination (HR) and non-homologous end-joining (NHEJ) (3) (4) (5) . The classic NHEJ (c-NHEJ) pathway frequently causes small alterations in DNA sequences around the break site, but rarely joins previously unlinked DNA ends (6) . However, there is an alternative (ALT) version of NHEJ that results in larger deletions and chromosomal translocations where DNA ends are joined at regions of DNA sequence microhomology (6, 7) . Notably, ALT-NHEJ activity is increased when the c-NHEJ pathway is down-regulated (6, 7) . Expression of both BCR-ABL1 and FLT3/ITD significantly alters the expression of key DSB repair components at both the mRNA and protein levels (8) and increases the frequency of repair errors (9) (10) (11) (12) . These cells also demonstrate increased in ALT-NHEJ activity characterized by large DNA deletions and repair using DNA sequence microhomologies (8, 13, 14) . Notably, treatment of BCR-ABL1-and FLT3/ITD-positive cells with TK inhibitors (TKIs) leads to decreased expression of ALT-NHEJ components LIG3 and PARP1 (8, 13, 14) and decreased DSB repair errors, indicating that altered DNA repair is due to one or more effectors of these signaling pathways (12) . However, the mechanisms responsible for this repair dysregulation were unknown.
There are several routes through which mammalian cells regulate gene expression, with transcriptional regulation being the most common mechanism. Both FLT3/ITD and BCR-ABL1-activated leukemias exhibit induction of the oncogenic transcription factor c-MYC (15, 16) . In turn, many downstream targets of c-MYC are transcriptionally activated, and this increased signaling that may result in enhanced survival and genomic instability (17) . In fact, c-MYC interacts with and regulates the promoters of DSB repair genes in several cancer cell lines (18) . While, the functional significance of this regulation remains unclear, these studies suggest that c-MYC might contribute to the DNA repair abnormalities observed in AML and CML cells with BCR-ABL1 and FLT3-ITD mutations. In addition, c-MYC has been shown to negatively regulate specific miRNAs, with c-MYC induction leading to repression of multiple miRNAs and miRNA clusters (19) .
In this study, we investigated the role of c-MYC in error-prone repair through increased expression of ALT-NHEJ factors LIG3 and PARP1 in cell lines and primary myeloid malignancies, and demonstrated that both c-MYC and c-MYC-regulated miRNAs, miR-150 and miR-22, contribute to increased levels of LIG3 and PARP1 expression, and consequently, ALT-NHEJ activity.
Materials and Methods

Patient samples
Frozen mononuclear cells (MNC) from Bone marrow (BM) and peripheral blood (PB) samples were obtained from CML patients [chronic-phase (CP) n=15, accelerated-phase (AP) n=1, blast crisis (BC) n=14] at the Marlene and Stewart Greenebaum Cancer Center and at the University of MilanoBicocca on protocols approved by the Institutional Review Board. BM MNC from healthy donors (HD) (Lonza) were used as controls for the patient samples.
Cell lines and Culture
The murine myeloid precursor cell lines 32Dcl3 and 32D-FLT3/ITD (kindly provided by Dr. Donald Small, Johns Hopkins University, Baltimore, MD), the human megakaryocytic cell lines MO7e and MO7e-BCR-ABL1 (kindly provided by Dr. Richard van Etten, Tufts University, Boston, MA), the human AML cell line MOLM14 (expressing FLT3/ITD), the human leukemia cell line REH (expressing wild-type FLT3), and the human CML cell line K562 (established from a patient in blast crisis (20) ) were grown as previously described. (11, 14) . 293Thuman embryonic kidney cells were grown in DMEM supplemented with 10% fetal bovine serum.
Plasmids
The c-MYC expression vectors pBABEpuro-myc-ER (plasmid 19128) and pcDNA3-cmyc (plasmid 16011) were obtained from Addgene (Cambridge, MA) and described in Ricci et al (21) . The luciferase expression vector pGL4.10 was obtained from Promega (Madison, WI). To construct the LIG3 promoter-reporter construct (pGL4.10-LIG3p), we cloned the LIG3 promoter from BAC clone 3143J8 (Invitrogen, Grand Island, NY) using Forward-AACCCTAACACCTCCTCTTCCTCT and Reverse-TGATCAAGGCTCCCTGAGTCCCA primers (IDT Technologies, Des Moines, IA). The cloned promoter was digested with NheI and EcoRV restriction enzymes (New England Biolabs, Ipswich, MA) and inserted into a digested pGL4.10 vector using a T4 ligase kit (Promega) according to the manufacturer's instructions. The PARP1 promoter-reporter construct was obtained from Switch Gear Genomics (Carlsbad, CA). The CAD promoter was cloned from genomic DNA isolated from normal human bone marrow (Lonza) using Forward-TGGGAGCCACCACTCTAT and Reverse-CGCATCACAGAGTGGGATAA primers, then digested with SacI restriction enzyme and cloned into pGL4.10 using T4 ligase kit. For site-directed mutagenesis of the c-MYC binding sites within the constructs above, we used the Q5 Site-Directed Mutagenesis kit (New England Biolabs) according to the manufacturer's instructions. All promoter-reporter reporter constructs were sequenced to confirm correct orientation and sequence of promoters, as well as success of site-directed mutagenesis. A GFP-expressing plasmid, pmaxGFP (Lonza), was used throughout the study to control for transfection efficiency. pEF1alpha-DsRed-Express 2 vector (Clontech) was used as a transfection efficiency control for experiments using pEGFP-Pem1-Ad2 vector.
Western blotting
Western blot analysis was performed as previously described (14) . c-MYC and Ku70 (Santa Cruz Biotechnology, Dallas, TX) antibodies were used at 1:500 and 1:1000, respectively. Anti-LIG3 (clone 7, BD Biosciences, San Jose, CA) and anti-PARP1 (Cell Signaling Technologies, Danvers, MA) were used at 1:3000. Anti-LIG4 (GeneTex) was used at 1:1000. Anti-GRB2 (Cell Signaling Technology) was used at 1:1000. Anti-actin antibody (Sigma, St Louis, MO) was used as a loading control at 1:10,000. Secondary antibodies conjugated to HRP (KPL, Gaitherburg, MD) were added at a 1:10,000 dilution. Signal was detected using ECL (GE Healthcare, Pittsburgh, PA). Bands were quantified with ImageQuant software (Bio-Rad, Hercules, CA).
Quantitative PCR
RNA isolation for real-time PCR of c-MYC, LIG3 and PARP1 transcripts was performed using the RNAspin mini-kit (GE Healthcare). Quantitect Primers (Qiagen, Germantown, MD) were used for each target, with GAPDH as housekeeping gene. Power SYBR ® Green RT-PCR Mastermix (Applied Biosystems, Foster City, CA) was used for reactions carried out in triplicates using a Mastercycler ep ® (Eppendorf, Hauppauge, NY). Relative quantification was determined using Eppendorf's realplex software according to the ΔΔC T method. For ChIP-qPCR, we used HotStart-IT SYBR Green qPCR 2X Mastermix (Affymetrix) per manufacturer's instructions.
Nanosting microRNA analysis
Paired CML-CP (n=5), CML-BC (n=5) and from HD (n=3) MNCs were processed using Ficoll-Paque plus (GE Healthcare Life Sciences). Total RNA was extracted with Trizol (Invitrogen) per manufacturer's instructions, and 100ng/sample was used to assess differences in miRNA expression using multiplexed NanoString enzyme-independent probe-based quantification system that allows digital counting of individual miRNA molecules (nCounter; NanoString Technologies, Seattle, WA), as previously described (22 Cells (2×10 6 , 0.5×10 6 per mL) were washed in Opti-MEM medium (Invitrogen) and transfected with SMARTpool siRNA (Thermo Scientific Dharmacon, Pittsburgh, PA) using the Amaxa Nucleofection System (Lonza) as previously described (14) .
MiRNAs
Total RNA was isolated using miRNeasy kit (Qiagen) per manufacturer's instructions. Levels of miRNAs were determined by Q-PCR using a TaqMan qRT-PCR kit (Life Technologies), with U18 serving as the housekeeping miRNA. miRNA expression and microarray analyses were carried out as previously described (23) . For miRNA-overexpression experiments, K562, MO7e-BCR/ABL1, and MOLM-14 cells were transfected with 50nM miR-34a, -22, -150, or a combination of miR-22 and -150 (Thermo Scientific-Dharmacon), and harvested for Western blot and NHEJ repair analyses at 24, 48, or 72hrs post transfection.
Chromatin Immunoprecipitation (ChIP)
ChIP was performed according to Luoto et al(18) , with the following modifications. Lysates were sonicated on ice 10 times using a Branson 450 Sonifier (Danbury, CT) for 10 seconds each time, at 40% output control and 2.5 duty-cycle, with 30-second refractory periods between sonications. ChIP products were purified using a Qiaquick kit (Qiagen) followed by q-PCR using the following primer sets: Reporter Assay System (Promega) using an HT Synergy plate reader (Bio-TEK, Winooski, VT).
In vivo NHEJ Assay
The in vivo NHEJ assay was performed as previously described (14) . Briefly, 0.2µg of linearized pUC18 plasmid was transfected into 2 million cells 48 hours post-transfection with siRNA against c-MYC or miR-22/150 combination, respectively. Repaired plasmid clones were sequenced at the repair junction, and sequences were analyzed using BioEdit sequence alignment editor (http://www.mbio.ncsu.edu/bioedit/bioedit.html). Three independent c-MYC-knockdown or miRNAoverexpression experiments, followed by three independent in vivo NHEJ assays were performed to confirm results. To determine the relative end-joining efficiency post siRNA knockdown, we utilized the GFP-based end-joining assay described by Fattah et al {Fattah, 2010 #11559}. Briefly, cells were transfected with siRNA for 48hrs, followed by transfection with HindIII-linearized pEGFP-Pem1-Ad2. Our previous studies showed that TK-activated leukemias had increased steady state levels of PARP1 and LIG3 mRNA and protein (24) , suggesting that they are transcriptionally regulated.
Following database analysis (using Matinspector from (Genomatix, Munich, Germany) and TF Search (Parallel Application TRC Laboratory, Japan) of promoter regions of these genes, c-MYC binding sites were revealed and thus c-MYC was investigated as a candidate in transcriptional regulation of these genes.
To determine whether c-MYC plays a role in regulating expression of LIG3 and PARP1, we initially examined microarray data for multiple myeloid leukemia cell lines and primary cells, to correlate mRNA expression levels of c-MYC with either LIG3 and PARP1 mRNA expression levels.
Analysis of acute myeloid leukemia (AML) cell lines (HL60, Kasumi1, KG1a, ML2, Mo7e, and U937), the BCR-ABL1+ CML cell line in BC K562, and primary AML patient samples (n=18 ; Table S1) revealed that endogenous levels of c-MYC showed a significant positive correlation, with levels of Given the strong correlation of c-MYC mRNA levels with LIG3 and PARP1 mRNA levels in AML, we hypothesized that increased c-MYC expression may augment expression of LIG3 and PARP1 in TK-activated leukemias, in which c-MYC is a known to be expressed at high levels (15, 16 (25), is not significantly altered ( Fig 1C, lower panel) .
c-MYC inhibition results in decreased LIG3 and PARP1 levels in FLT3/ITD-and BCR-ABL1-positive cells.
Next, to determine whether depletion of endogenous c-MYC results in decreased levels of LIG3 and PARP1 transcripts and proteins, siRNA-mediated knockdown of c-MYC was performed in MO7e-BCR-ABL1 and 32D-FLT3/ITD, followed by Q-PCR and Western blotting analysis of mRNA and protein levels, respectively. To ensure that observed effects of siRNA-mediated c-MYC knockdown were not due to cell death, we performed experiments over a 48-hour period and confirmed cell viability by trypan blue dye exclusion as well as by MTS-based viability assays (Supplementary Fig.   S1A and B). SiRNA-mediated knockdown, using pooled oligonucleotides of c-MYC (>50%) led to a significant reduction (p< 0.01) in both mRNA and protein levels of LIG3 and PARP1 ( (Fig. 2D) . We also used a well-established c-MYC overexpression model (21) in which the c-MYC expression vector, pcDNA3-cmyc, is cotransfected into 293T cells along with PARP1 and LIG3 promoter luciferase constructs and luciferase activity is measured in comparison to empty vector pcDNA3 controls. C-MYC over-expression ( Fig.   2E ) resulted in 2.5-fold (p=0.013) and 1.8-fold (p=0.005) increase in LIG3 and PARP1 promoter activities, respectively. Notably, when compared to parental controls, LIG3 and PARP1 luciferase activity levels were similar to those in TK-positive cells (2-to 3-fold increase, Fig. 2C ). Furthermore, site-directed mutagenesis of the highest-probability c-MYC binding sites (as determined by Genomatix software) within the LIG3 and PARP1 promoter-reporter constructs ( Fig. 2A) , resulted in a significant decrease in LIG3 (40%; p= 0.02) and PARP1 (30%; p= 0.004) promoter activities, compared to cells transfected with wild-type promoter-reporter vectors (Fig. 2E) . Importantly, cells transfected with the mutant promoter-reporter constructs showed significantly decreased luciferase activity, compared to controls (Fig. 2E) . We obtained similar results as above using a promoterreporter vector of carbamoyl-phosphate synthase 2 (CAD), a well-established target of c-MYCinduced transcription (29) , as a positive control (Fig. S2B) .
To determine whether c-MYC actually binds to the promoters of the LIG3 and PARP1 genes and to confirm the ChIP-seq data (from ENCODE) observed in K562 cells (Fig 2B) , we performed chromatin immunoprecipitation (ChIP) in extracts from MO7e-BCR-ABL1-positive ( (Fig. 3A and B) . Imatinib treatment of MO7e-BCR-ABL1 cells resulted in smaller (20-30%) yet significant decrease (p<0.04) in mRNA and protein levels of c-MYC, LIG3 and PARP1
( Fig. 3A and B) . As seen in Fig. 3C , TKI treatment of MOLM14 and MO7e-BCR-ABL1 resulted in similar effects on the protein levels of LIG3 and PARP1 as was observed for mRNA levels ( Fig. 3A and B). Of note, we did not observe the presence of cleaved PARP1 band (Fig. 3C) , suggesting that the downregulation observed was not a result of the cells undergoing apoptosis. To ensure that PARP1 can undergo cleavage at this time point, we treated cells with 50nM (MOLM14) or 1uM (MO7e-BCR-ABL1) etoposide and demonstrated PARP1 cleavage (Fig. 3D) . Given that c-MYC phosphorylation at Serine 62 (Ser62) is an indication of its signaling activity (31), we performed Western blotting analysis for this c-MYC phosphorylation site following treatment with the TKIs described above and showed that phospho-Ser62 is decreased significantly following treatment in both cell lines (Fig. 3E) . 
BCR-ABL1-positive cells.
C-MYC is known to specifically regulate expression of multiple miRNAs, the majority of which undergo negative regulation by this transcription factor (19) . To determine whether c-MYC-mediated decrease in miRNAs levels in leukemia cells may be an additional mechanism of LIG3 and PARP1 regulation, we examined the 3'-UTR and coding sequences of LIG3 and PARP1 for potential c-MYCregulated miRNA binding sites (Table S2 ). LIG3 and PARP1 are predicted targets of multiple c-MYCregulated miRNAs, including miR-22, miR-27a, miR-34a, and miR-150. In our initial studies, we used microarray analysis of mRNA expression and mature miRNA levels from multiple AML cell lines and primary samples (Table S1 ) shown in Fig. 1 A and Fig. 4C ). In contrast, miR-34a showed neither a positive nor inverse correlation with either LIG3 or PARP1 (Fig.   S3A) . While miR-27a demonstrated an inverse correlation with PARP1, it did not significantly correlate with LIG3 (Fig. S3B) . Accordingly, we focused on miR-22 and miR-150 for the remainder of this study. (Fig. S3D) .
Transfection of a combination of miR-22 and -150 produced an approximately 35-40% decrease in LIG3 (p<0.05) and PARP1 (p<0.05) protein levels, compared to MOLM14, and MO7e-BCR-ABL1 cells transfected with a non-specific control (NSC) miRNA (Fig. 4D, E) .
Depletion of c-MYC and overexpression of c-MYC-regulated miR-150 and miR-22 decrease
ALT-NHEJ activity in FLT3/ITD-and BCR-ABL1-positive cells.
To determine whether c-MYC regulation of key ALT-NHEJ components in TK-activated leukemias also plays a role in ALT-NHEJ repair activity, we performed an established in vivo plasmid-based end-joining assay (11, 12, 32, 33) following chemical and siRNA inhibition of c-MYC. In this assay (Fig. 5A ), pUC18 plasmid is linearized by restriction-enzyme digestion to simulate a DSB, then transfected into cells. The repaired plasmid is isolated from cells and transformed into DH5α bacteria, which are then plated on agar plates. Colonies (representing clones of one repaired plasmid) are picked for plasmid isolation and sequencing of repair junctions. C-MYC was inhibited in MOLM14 and MO7e-BCR/ABL1 using chemical inhibition (10058-F4) or siRNA technology, followed by the above end-joining assays. c-MYC knockdown and consequent decrease in LIG3 and PARP1 levels were confirmed by Western blot analysis ( Fig. S4A and B) . We also verified that the transfection efficiency of the linearized pUC18 plasmid was not affected by c-MYC knockdown by co-transfection with a GFP-expressing vector (Fig. S4C) . Approximately 30 colonies from three independent experiments were analyzed by colony PCR and sequencing of the region that encompasses the repaired DSB.
MOLM14 cells depleted of c-MYC by chemical inhibition had a general reduction in the size of DNA
deletions when compared to DMSO-treated cells (Fig. 5B, p<0.015) . Similar results were obtained following siRNA-mediated knockdown of c-MYC in MO7e-BCR-ABL1 cells ( Figure 5C , p<0.05).
Importantly, repair assays performed with linearized pUC18 DNA controls showed very few colonies (Fig S4D) . In addition, we analyzed the data for the proportion of large deletions (>20bps) vs small deletions (<20bps) that are characteristic of c-NHEJ (Fig. S4E) repaired in Tk-activated cell lines MOLM14 and MO7e-BCR-ABL1 with small deletions occurring at the repair junctions. Following, siRNA knockdown of c-MYC, the fraction of small deletions actually increases significantly (Fig. S4E) . In fact, siRNA knockdown of c-MYC results in a slight but insignificant increase in NHEJ efficiency using a different NHEJ reporter (pEGFP-Pem1-Ad2) assay {Fattah, 2010 #11559}. In contrast, knockdown of control c-NHEJ factor, LIG4, reduces NHEJ efficiency significantly (Fig S4F, G) . This suggests that c-MYC may not contribute significantly to c-NHEJ activity.
Moreover, c-MYC depletion decreased the frequency of microhomology-mediated repair (Fig. 5D,   p<0 .05). Notably, overexpression of miR-150 and miR-22 in MO7e-BCR-ABL1 cells produced the same results seen with c-MYC inhibition ( Fig. 5E and 5F ). The reduction in LIG3 and PARP1 protein levels post miR overexpression was confirmed by Western blot analysis (Fig. S4H ).
c-MYC mRNA levels correlate with LIG3 and PARP1 mRNA and inversely correlate with miR-22 and -150 in primary samples from CML patients
To determine whether primary CML samples demonstrated increased expression levels of c-MYC and decreased levels of miR-150 and -22, we first examined mRNA samples from 21 CML patients (Table 1 ) and compared transcript levels of c-MYC, LIG3 and PARP1 in peripheral blood (PB) and bone marrow (BM) mononuclear cells (MNC) samples with those of normal bone marrow (BM) controls. As seen in Fig. 6A and B, there was a strong positive correlation between c-MYC mRNA levels and LIG3 (Pearson's r = 0.88, p<0.001) and PARP1 (Pearson's r = 0.84, p<0.001) mRNA levels. c-MYC expression was increased in twelve of twenty-one (57%), compared with normal controls, Of the twelve CML samples with increased c-MYC levels, nine (75%) also had increased levels of LIG3 and PARP1 (Table 1) . In these samples with increased levels of c-MYC, PARP1 and LIG3, there was there was no bias towards a particular disease phase, or response to TKIs. Interestingly, however, two of three TKI-resistant CML patients (Table 1 , PT #8, and #16) with T315I-BCR-ABL1 mutations (34, 35) had increased levels of c-MYC, LIG3 and PARP1.
CML patient samples were next evaluated for expression of c-MYC-regulated miRs. We first examined mRNA for miR-150 in a sub-set of the above-described patient samples (n=8; Table 1, PT #6, #8, #13, #17, #18, #20, #21) for which mRNA was available and 2 additionally acquired CML patients (Table S3 ; #22 in chronic phase and #23 in blast crisis) by miRNA Q-PCR analysis and compared results to normal bone marrow cells (NBMC) (n=2). There was a significant decrease (p<0.05) in c-MYC-repressed miR-150 levels in all CML samples, compared to NBMC (Fig. 6C) . We next examined miR-22 expression levels in CML patient samples in chronic phase (N=4 ; Table S3; PT #13, #24, #25, and #26) vs those in in blast crisis (N=4 ; Table S3 ; #8, #18, #20, and #23). In contrast to results with miR-150, miR-22 expression levels appear to be decreased significantly (p<0.01) in CML-BC patients when compared to CML-CP patients (Fig. 6D) . To confirm these data, we analyzed NanoString mIR expression arrays (courtesy of Perrotti and Gambacorti laboratories, unpublished observations) from a separate cohort of CML patient mRNAs from paired MNC samples of CML-CP (n=5) and -BC (n=5) patients and HD (healthy donors, n=3) controls. As expected from the earlier correlation studies (Fig. S3B) , miR-27a showed no significant differences in expression between CML patient samples and HD controls (Fig. 6E) . In contrast, and as seen in the first cohort of CML patient samples (Fig. 6C) , levels of miR-150 were significantly decreased in both CP and BC compared to HD, and there were no significant expression differences between CP and BC in the 5 paired patient samples examined (Fig. 6E) . Similar to the above results (Fig. 6D) , compared with HD controls, miR-22 expression was decreased significantly only in BC, compared with HD controls (Fig.   6E ). Therefore similar studies are merited for other DSB repair genes. Thus, while increased ALT NHEJ activity may be a plausible mechanism for genomic instability, and studies that measure actual chromosomal instability are warranted (38) . 
The most extensively utilized point of gene regulation is at the level of transcription, while miRNAs are thought to be involved in "fine-tuning" gene regulation. miRNAs are involved in the regulation of many cancer-specific signaling pathways in hematopoiesis, and are aberrantly expressed in hematologic malignancies (39) . c-MYC is known to negatively regulate a group of miRNAs, which is thought to contribute to tumorigenesis (19) . In the context of LIG3 and PARP1 regulation, we propose in addition to its transcriptional regulation of these genes, c-MYC also represses miRNAs (miR-22 and miR-150) that target LIG3 and PARP1 transcripts. Indeed, this dual regulation by c-MYC was previously reported; c-MYC was shown to regulate the transcription factor E2F1 through direct transcription and activation of miRNAs that target E2F1 (40) . Another group showed that expression of EZH2, a protein involved in regulation of gene expression, was amplified as a result of c-MYC-mediated repression of miR-26a, which targets EZH2 (41).
We previously reported that treatment of BCR-ABL1-and FLT3/ITD-positive cells with TK inhibitors (TKIs) leads to decreased expression of the ALT-NHEJ components LIG3 and PARP1 (8, 13, 14) and decreased DSB repair errors, indicating that the altered DNA repair is due to one or more of the effectors of these signaling pathways (12) . Our studies here show that the downstream TK From a therapeutic standpoint, targeting c-MYC in leukemia may not be a viable option, considering the myriad of roles c-MYC plays in normal cells. However, the identification of other "drugable" downstream targets of c-MYC may be considered. With respect to our current study, PARP1 represents an attractive target for therapy, as PARP1 inhibitors are currently used in the clinic, and new ones are being investigated in clinical trials. In fact, a recent study by our collaborators demonstrated that PARP1 inhibition is synthetically lethal in TK-driven leukemias that exhibit defects in the HR pathway (47) . Therefore, given that DSBs are lethal if not repaired, the c-MYC downstream targets LIG3 and PARP1 and other DSB repair factors may be attractive targets for therapy (48) . 
